AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, today announced that a new poster is online at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. The work, conducted with researchers from the Italian Group for Mesothelioma (GIMe) and collaborators, provides the first evidence that selective inhibition of the adenosine A2B receptor exerts a direct antitumor effect in epithelial and non-epithelial mesothelioma cells, decreases pCREB with an associated reduction in PD-L1 expression, and modulates signaling YAP consistent with proteomic changes, alongside immune-mediated growth inhibition.
These results reinforce previous preclinical results with Cyncado’s selective A2B receptor antagonist TT-4 in mesothelioma, where the activity of the monotherapy exceeded anti-PD-1 and the combination with anti-PD-1 further improved tumor control, accompanied by increased immune infiltration and tertiary lymphoid structures. The new mechanistic data help explain the previously observed efficacy profile and support translation to first-in-human evaluation.
In human mesothelioma spheroid systems, hypoxia-related adenosine signals increased tumor growth and PD-L1 expression. Selective inhibition of the A2B receptor reduced cell growth and PD-L1 protein through reduced phosphorylation of CREB (pCREB). In mouse models, TT-4 blocked NECA-induced pCREB activation and growth stimulation in AB1 and AB22 mesothelioma cells. In vivo, TT-4 demonstrated significant activity as monotherapy in an immunocompetitorThe mesothelioma model and combined treatment with anti-PD-1 further increased tumor growth inhibition, with immunohistochemistry showing higher T cell infiltration.
“Mesothelioma is a hypoxic, adenosine-rich disease, and these data add a clear tumor-intrinsic mechanism to the case for targeting the A2B receptor,” said Rob Kramer, PhD, chief scientific officer at Cyncado Therapeutics. “We are advancing TT-4 toward administration to the first patient in the first quarter of 2026 to translate these signals clinically. »
“AlphaTON is focused on programs where biology and translational markers converge,” said Brittany Kaiser, Managing Director of AlphaTON Capital. “This body of early evidence strengthens our belief in TT-4 for mesothelioma and informs how we prioritize resources to achieve proof of concept in patients. »
Clinical Program Status
• TT-10 (A2A receptor antagonist): phase 1 dose escalation is underway in advanced solid tumors.
• TT-4 (A2B receptor antagonist): IND compatible program preparing for administration to the first patient in the first quarter of 2026.
AACR-NCI-EORTC Poster Details
Title: Inhibition of ADORA2B in mesothelioma (MMe) cells affects PD-L1 expression and exerts an effective response on AKT signaling and anti-tumor immune response
Session: Poster Session C
Date and time: Today, Saturday October 25, 2025, 12:30 p.m. – 4:00 p.m.
Presentation group: GIMe with collaborators from the University of L’Aquila, the Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, St. James Hospital Dublin and Cyncado Therapeutics
About AlphaTON Capital Corp.
AlphaTON Capital is a digital asset treasury company focused on creating and managing a strategic reserve of TON tokens and developing the Telegram ecosystem. The company implements a comprehensive treasury strategy that combines direct token acquisition, validation operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, AlphaTON Capital provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram’s billion-user platform while maintaining the governance standards and reporting transparency of a Nasdaq-listed company.
Led by Managing Director Brittany Kaiser and Chief Investment Officer Enzo Villani, the company’s activities span network validation and staking operations, Telegram-based application development, and potential strategic investments in TON-based decentralized financial protocols, gaming platforms, and commercial applications. AlphaTON Capital Corp is incorporated in the British Virgin Islands and is listed on Nasdaq under the ticker symbol. ATON.
AlphaTON Capital, through its legacy businesses, is also advancing potentially first-in-class therapies that target known checkpoint resistance pathways to potentially achieve a durable therapeutic response and improve patients’ quality of life. AlphaTON Capital actively engages in the drug development process and provides strategic advice to guide the development of new immunotherapy assets and combinations of assets.
About Cyncado Therapeutics
Tarus Therapeutics, LLC (doing business as Cyncado Therapeutics), a wholly owned subsidiary of AlphaTON Capital Corp, is currently developing potentially best-in-class small molecule adenosine receptor antagonists targeting A2A and A2B receptors to overcome immune suppression in oncology. The Company’s lead program, TT-4, is an ultra-selective oral A2B receptor antagonist, initially focused on mesothelioma, and is expected to be administered to the first patient in the first quarter of 2026. Cyncado is also developing dual-antagonist strategies designed to achieve complete blockade of adenosine-mediated immune evasion, potentially unlocking effects synergistic antitumor drugs and durable patient responses.
Forward-looking statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements other than statements of historical fact, including statements regarding the Company’s business strategy, plans and objectives, future operations, clinical development timelines, growth of the TON ecosystem, therapeutic development results, regulatory approvals and statements preceded by, followed by or including words such as “believe”, “expect”, “anticipate”, “a intends to”, “estimates”, “will”, “may”, “plans”, “potential”, “targets” or similar expressions are forward-looking statements.
These forward-looking statements are subject to significant risks and uncertainties, including, but not limited to: regarding clinical trial results and regulatory approvals; the uncertainty of the Company’s investment in TON and digital assets; regulatory and legal risks associated with digital assets; risks related to the Telegram platform and the TON ecosystem; market volatility; competitive risks in digital assets and therapeutic product development; and other factors described in “Item 3 – Key Information – Risk Factors” in the Company’s Annual Report on Form 20-F for the fiscal year ended March 31, 2025, and subsequent reports filed with the Securities and Exchange Commission.
Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, actual results may differ materially. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.
Contact details
Investor Relations
AlphaTON Capital Corp.
(email protected)
(203) 682-8200
Media inquiries
Richard Laermer
RP RLM
(email protected)
(212) 741-5106 ext. 216
